Mostrar el registro sencillo

dc.contributor.authorQuevedo-Abeledo, Juan C.
dc.contributor.authorHernández Díaz, Marta
dc.contributor.authorGarcía González, María
dc.contributor.authorGómez Bernal, Fuensanta
dc.contributor.authorAlmeida Santiago, Cristina
dc.contributor.authorHeras Recuero, Elena
dc.contributor.authorDe Vera-González, Antonia
dc.contributor.authorGonzález Delgado, Alejandra
dc.contributor.authorAbreu González, Pedro
dc.contributor.authorTejera Segura, Beatriz f
dc.contributor.authorMartín González, Candelaria
dc.contributor.authorGonzález-Gay Mantecón, Miguel Ángel 
dc.contributor.authorFerraz Amaro, Iván
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2025-10-17T09:09:37Z
dc.date.available2025-10-17T09:09:37Z
dc.date.issued2025
dc.identifier.issn2076-3921
dc.identifier.urihttps://hdl.handle.net/10902/37901
dc.description.abstract3-Nitrotyrosine (3-NT) is a product of tyrosine nitration mediated by reactive nitrogen species such as peroxynitrite anion and nitrogen dioxide. It serves as an indicator of inflammation, cell damage, and nitric oxide production. Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by multisystem involvement and increased oxidative stress. Notably, cardiovascular (CV) disease has emerged as the leading cause of mortality among SLE patients. Our objective was to investigate the association between serum 3-NT levels and a wide range of disease characteristics in patients with SLE, with a particular emphasis on CV comorbidity. A total of 214 patients with SLE were enrolled. The serum levels of 3-NT as well as the activity (SLEDAI) and damage index (SLICC-SDI) scores, full lipid profile, insulin resistance indices, and carotid subclinical atherosclerosis were assessed. Multivariable linear regression analysis was carried out to study the relationship between 3-NT and clinical and laboratory disease characteristics, especially focusing on CV comorbidities. Except for body mass index, which showed a significant positive correlation, the demographic data and traditional CV risk factors did not correlate with 3-NT. After multivariable adjustments, several disease characteristics, including the disease duration, activity and damage indices, and autoantibody profile, showed significant positive associations with 3-NT. Regarding CV characteristics, several lipid profile molecules showed significant relationships with 3-NT. This was not the case for insulin resistance and subclinical atherosclerosis. Remarkably, patients with a high CV risk by SCORE2 showed higher 3-NT values compared to those with a low risk, although after the multivariable adjustment, this relationship was attenuated (but still showed a trend). In conclusion, serum 3-NT levels demonstrated significant positive correlations with multiple disease characteristics, including the disease activity and damage and the autoantibody profile. The lipid pattern in the SLE subjects also significantly and independently correlated with the 3-NT values. Our findings highlight the pathophysiological role of 3-NT specifically, and peroxidation in general, in patients with SLE.es_ES
dc.description.sponsorshipThis study has been funded by a grant to IF-A by Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC) through the project PIFIISC23/07. Professor Gonzalez-Gay is funded by the Spanish Research Network RICORS—RD24/0007/0031, through Next Generation EU funds, which support the initiatives of the Recovery and Resilience Mechanism (MRR).es_ES
dc.format.extent14 p.es_ES
dc.language.isoenges_ES
dc.rights© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.es_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceAntioxidants, 2025, 14(6), 739es_ES
dc.subject.other3-nitrotyrosinees_ES
dc.subject.otherSystemic lupus erythematosuses_ES
dc.subject.otherDisease damagees_ES
dc.subject.otherCardiovascular diseasees_ES
dc.titleSerum 3-nitrotyrosine in the cardiovascular disease of patients with systemic lupus erythematosuses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.3390/antiox14060739es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.3390/antiox14060739
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.Excepto si se señala otra cosa, la licencia del ítem se describe como © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.